Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912532 | 0.81 | CYP1A2 (0.49) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL6842368 | 0.76 | CYP1A2 (0.50) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL13078313 | 0.74 | CA1 (0.53) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL8446912 | 0.74 | CA1 (0.53) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL1731214 | 0.74 | CYP1A2 (0.51) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL26489244 | 0.74 | CYP1A2 (0.51) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL7803484 | 0.74 | CYP1A2 (0.54) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL15663302 | 0.74 | CYP1A2 (0.54) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL14357345 | 0.74 | CYP1A2 (0.54) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL20313909 | 0.73 | CA1 (0.48) | CA1CA2CA7CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750162-B2 | Process for preparation of nonnatural amino acid and intermediate thereof | DAISO CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20070208180-A1 | Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof | DAISO CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1739077-A1 | PROCESS FOR PRODUCTION OF NONNATURAL AMINO ACIDS AND INTERMEDIATES THEREFOR | DAISO CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208180-A1 | Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof | BCAT1, BCAT2, AADAT | CA1 2028/4885CA2 4192/4885CA7 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.